Literature DB >> 20844234

Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.

Ebenezer David1, Jonathan L Kaufman, Christopher R Flowers, Katherine Schafer-Hales, Claire Torre, Jing Chen, Adam I Marcus, Shi-Yong Sun, Lawrence H Boise, Sagar Lonial.   

Abstract

In this report, we investigated the mechanism responsible for synergistic induction of myeloma cell apoptosis induced by the combination of tipifarnib and bortezomib. Immunofluorescence studies revealed that bortezomib alone resulted in an accumulation of puncta of ubiquitinated proteins that was further enhanced by the addition of tipifarnib. These data suggest inhibition of the degradation of bortezomib-induced aggresomes; and consistent with this possibility, we also observed an increase in p62SQSTM1 in cells treated with the combination. However, autophagy in these cells appears to be normal as LC3BII is present, and autophagic flux appears to be unaffected as demonstrated by the addition of bafilomycin A₁. Together, these data demonstrate that tipifarnib synergizes with bortezomib by inducing protein accumulation as a result of the uncoupling of the aggresome and autophagy pathways.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20844234      PMCID: PMC4347258          DOI: 10.1182/blood-2010-03-272393

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Aggresomes, inclusion bodies and protein aggregation.

Authors:  R R Kopito
Journal:  Trends Cell Biol       Date:  2000-12       Impact factor: 20.808

2.  Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

Authors:  Laurence Catley; Ellen Weisberg; Tanyel Kiziltepe; Yu-Tzu Tai; Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Peter Atadja; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.

Authors:  Teru Hideshima; James E Bradner; Jason Wong; Dharminder Chauhan; Paul Richardson; Stuart L Schreiber; Kenneth C Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

Review 4.  Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies.

Authors:  N Reddy; M S Czuczman
Journal:  Ann Oncol       Date:  2010-02-04       Impact factor: 32.976

5.  Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

Authors:  Steffan T Nawrocki; Jennifer S Carew; Maria S Pino; Ralph A Highshaw; Robert H I Andtbacka; Kenneth Dunner; Ashutosh Pal; William G Bornmann; Paul J Chiao; Peng Huang; Henry Xiong; James L Abbruzzese; David J McConkey
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

Review 6.  Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome.

Authors:  Wen-Xing Ding; Xiao-Ming Yin
Journal:  Autophagy       Date:  2007-10-19       Impact factor: 16.016

Review 7.  The aggresome pathway as a target for therapy in hematologic malignancies.

Authors:  Tiffany Simms-Waldrip; Agustin Rodriguez-Gonzalez; Tara Lin; Alan K Ikeda; Cecilia Fu; Kathleen M Sakamoto
Journal:  Mol Genet Metab       Date:  2008-05-09       Impact factor: 4.797

8.  Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

Authors:  Judith E Karp; Karen Flatten; Eric J Feldman; Jacqueline M Greer; David A Loegering; Rebecca M Ricklis; Lawrence E Morris; Ellen Ritchie; B Douglas Smith; Valerie Ironside; Timothy Talbott; Gail Roboz; Son B Le; Xue Wei Meng; Paula A Schneider; Nga T Dai; Alex A Adjei; Steven D Gore; Mark J Levis; John J Wright; Elizabeth Garrett-Mayer; Scott H Kaufmann
Journal:  Blood       Date:  2008-12-24       Impact factor: 22.113

9.  Selective turnover of p62/A170/SQSTM1 by autophagy.

Authors:  Yoshinobu Ichimura; Eiki Kominami; Keiji Tanaka; Masaaki Komatsu
Journal:  Autophagy       Date:  2008-11-20       Impact factor: 16.016

10.  Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.

Authors:  Jennifer S Carew; Ernest C Medina; Juan A Esquivel; Devalingam Mahalingam; Ronan Swords; Kevin Kelly; Hui Zhang; Peng Huang; Alain C Mita; Monica M Mita; Francis J Giles; Steffan T Nawrocki
Journal:  J Cell Mol Med       Date:  2010-10       Impact factor: 5.310

View more
  12 in total

1.  Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.

Authors:  Antonia Cagnetta; Michele Cea; Teresa Calimeri; Chirag Acharya; Mariateresa Fulciniti; Yu-Tzu Tai; Teru Hideshima; Dharminder Chauhan; Mike Y Zhong; Franco Patrone; Alessio Nencioni; Marco Gobbi; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2013-07-03       Impact factor: 22.113

Review 2.  The Tao of myeloma.

Authors:  Lawrence H Boise; Jonathan L Kaufman; Nizar J Bahlis; Sagar Lonial; Kelvin P Lee
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

3.  Cellular localization of NLRP3 inflammasome.

Authors:  Yan Wang; Chen Yang; Kairui Mao; Shuzhen Chen; Guangxun Meng; Bing Sun
Journal:  Protein Cell       Date:  2013-04-23       Impact factor: 14.870

4.  Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.

Authors:  Michele Cea; Antonia Cagnetta; Chirag Acharya; Prakrati Acharya; Yu-Tzu Tai; Cao Yang; Davide Lovera; Debora Soncini; Maurizio Miglino; Giulio Fraternali-Orcioni; Luca Mastracci; Alessio Nencioni; Fabrizio Montecucco; Fiammetta Monacelli; Alberto Ballestrero; Teru Hideshima; Dharminder Chauhan; Marco Gobbi; Roberto M Lemoli; Nikhil Munshi; Steven P Treon; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2016-06-10       Impact factor: 12.531

5.  Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.

Authors:  Aluvia M Escalante; Ryan T McGrath; Matthew R Karolak; Robert T Dorr; Ronald M Lynch; Terry H Landowski
Journal:  Cancer Chemother Pharmacol       Date:  2013-04-10       Impact factor: 3.333

6.  Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells.

Authors:  Li Jia; Ganga Gopinathan; Johanna T Sukumar; John G Gribben
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

7.  Vimentin and PSF act in concert to regulate IbeA+ E. coli K1 induced activation and nuclear translocation of NF-κB in human brain endothelial cells.

Authors:  Feng Chi; Tao Bo; Chun-Hua Wu; Ambrose Jong; Sheng-He Huang
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

Review 8.  DangER: protein ovERload. Targeting protein degradation to treat myeloma.

Authors:  Lauren I Aronson; Faith E Davies
Journal:  Haematologica       Date:  2012-05-11       Impact factor: 9.941

9.  Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells.

Authors:  Holger W Auner; Anne Marie Moody; Theresa H Ward; Marianne Kraus; Enrico Milan; Philippa May; Aristeidis Chaidos; Christoph Driessen; Simone Cenci; Francesco Dazzi; Amin Rahemtulla; Jane F Apperley; Anastasios Karadimitris; Niall Dillon
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

10.  The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells.

Authors:  Mohamed-Amine Hamouda; Nathalie Belhacene; Alexandre Puissant; Pascal Colosetti; Guillaume Robert; Arnaud Jacquel; Bernard Mari; Patrick Auberger; Frederic Luciano
Journal:  Oncotarget       Date:  2014-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.